This item is not intended to be used as a drug, supplement, or cosmetic, and must not be misrepresented as such
Trial-Reported Endpoints by Phase Trial Lancet 2021 Phase 2 Duration 26 weeks Population Overweight/obese, no T2D (n=706) Mean Weight Loss 10.8% at 4.5 mg vs 3.0% placebo Trial Lancet 2023 Phase 2 Duration 32 weeks Population T2D + obesity (n=92) Mean Weight Loss 8.1% cagrilintide alone
Most importantly, neither agent has raised major red flags in terms of serious adverse events in the trials conducted to date
Originally developed to study metabolic disorders and insulin resistance , 5-Amino-1MQ has now gained attention in fitness and longevity circles for its ability to: Reduce fat cell size Increase NAD levels (critical for energy and mitochondrial function) Enhance insulin sensitivity and metabolic efficiency When NNMT is overactive as is often the case with obesity, aging, and chronic disease it limits the availability of nicotinamide and reduces NAD production
Certain bulk drug substances for use in compounding that may present significant safety risks (Category 2)
M.DanielM.GunnJ